Details:
The proceeds from the financing will enable Anjarium to expand its ground-breaking platform that combines proprietary DNA-based gene vectors, natural and synthetic nanoparticle delivery modalities – including its novel HybridosomeTM technology & progress therapeutic pipeline.
Lead Product(s): DNA-based Gene Vectors
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Abingworth
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 16, 2021